- Home
- Publications
- Publication Search
- Publication Details
Title
RTK Inhibitors in Melanoma: From Bench to Bedside
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 7, Pages 1685
Publisher
MDPI AG
Online
2021-04-02
DOI
10.3390/cancers13071685
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
- (2020) Emerson Soares Veloso et al. BMC Veterinary Research
- Bevacizumab treatment of meningeal melanoma metastases
- (2020) Trude G. Simonsen et al. Journal of Translational Medicine
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
- (2019) Karwaciak et al. Cancers
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells
- (2019) Senthil R. Kumar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
- (2019) Felicity Newell et al. Nature Communications
- Fibroblast Growth Factor Receptor Signaling in Skin Cancers
- (2019) Malgorzata Czyz Cells
- Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
- (2019) Aasen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
- (2019) Ishani Das et al. Cell Death & Disease
- Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
- (2019) Aleksandra Simiczyjew et al. Frontiers in Pharmacology
- FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR
- (2019) Lei Li et al. BMC CANCER
- Pexidartinib: First Approval
- (2019) Yvette N. Lamb DRUGS
- Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
- (2019) Maria Grazia Atzori et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma
- (2019) Yara Abdou et al. MEDICINE
- Structural basis of the activation of type 1 insulin-like growth factor receptor
- (2019) Jie Li et al. Nature Communications
- Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
- (2019) Ewelina Dratkiewicz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
- (2018) P G Corrie et al. ANNALS OF ONCOLOGY
- The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells
- (2018) Daniela Dörfel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
- (2018) Julie Delyon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets
- (2018) Jiong Lyu et al. JOURNAL OF PATHOLOGY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway
- (2018) Xuefeng Wan et al. Molecular Medicine Reports
- Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
- (2018) Ewelina Dratkiewicz et al. Oncotarget
- Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model
- (2018) István Kenessey et al. MELANOMA RESEARCH
- Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study
- (2018) Xiaoting Wei et al. ONCOLOGY RESEARCH
- Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
- (2018) Josip Skoko et al. BMC CELL BIOLOGY
- HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
- (2018) Federica Papaccio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma
- (2018) Meredith McKean et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma
- (2017) Jennifer D. Hintzsche et al. MELANOMA RESEARCH
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
- (2017) Felicity MacDonald et al. Frontiers in Pharmacology
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
- (2017) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma
- (2017) L. A. Fecher et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
- (2017) Helena A. Yu et al. Journal of the National Comprehensive Cancer Network
- Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation
- (2016) Lucia Kucerova et al. BMC CANCER
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
- (2016) Jin S. Im et al. PLoS One
- The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
- (2015) A P Algazi et al. BRITISH JOURNAL OF CANCER
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma
- (2015) Elizabeth I. Buchbinder et al. CANCER
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- (2015) R. D. Carvajal et al. CLINICAL CANCER RESEARCH
- Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
- (2015) Hui-Hui Cao et al. Molecular Cancer
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
- (2015) K. T. Flaherty et al. ONCOLOGIST
- Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)
- (2015) S. J. Lee et al. ONCOLOGIST
- A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma
- (2015) Tejaswi V. Mudigonda et al. Pigment Cell & Melanoma Research
- PTEN regulates IGF-1R-mediated therapy resistance in melanoma
- (2015) Jun Wang et al. Pigment Cell & Melanoma Research
- The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids
- (2015) George Hedger et al. Scientific Reports
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Phenotype Switching in Melanoma: Implications for Progression and Therapy
- (2015) Frederic Zhentao Li et al. Frontiers in Oncology
- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- Targeting c-Met in melanoma
- (2014) Deven Etnyre et al. CANCER BIOLOGY & THERAPY
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- Different Epidermal Growth Factor (EGF) Receptor Ligands Show Distinct Kinetics and Biased or Partial Agonism for Homodimer and Heterodimer Formation
- (2014) Jennifer L. Macdonald-Obermann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma
- (2014) Suthee Rapisuwon et al. MELANOMA RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
- (2014) Leonard Appleman et al. OncoTargets and Therapy
- Receptor Tyrosine Kinases: Legacy of the First Two Decades
- (2014) J. Schlessinger Cold Spring Harbor Perspectives in Biology
- Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling
- (2013) Hui-Hui Cao et al. BIOCHEMICAL PHARMACOLOGY
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Characterization of KIT mutation in melanoma
- (2013) Chi-Yuan Tzen et al. Dermatologica Sinica
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts
- (2013) Jon-Vidar Gaustad et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells
- (2013) Jason R. Todd et al. Pigment Cell & Melanoma Research
- Why is melanoma so metastatic?
- (2013) Russell R. Braeuer et al. Pigment Cell & Melanoma Research
- Progress in cancer therapy targeting c-Met signaling pathway
- (2012) Kyung Hee Jung et al. ARCHIVES OF PHARMACAL RESEARCH
- Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts
- (2012) Jon-Vidar Gaustad et al. BMC CANCER
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
- (2012) W. Wang et al. CLINICAL CANCER RESEARCH
- Sunitinib Therapy for Melanoma Patients withKITMutations
- (2012) David R. Minor et al. CLINICAL CANCER RESEARCH
- The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
- (2012) Fabiola Cecchi et al. Current Signal Transduction Therapy
- EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling
- (2012) Kristy J. Wilson et al. GROWTH FACTORS
- Targeting Oncogenic Drivers and the Immune System in Melanoma
- (2012) Grant A. McArthur et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model
- (2012) Anamika Bose et al. MELANOMA RESEARCH
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
- (2012) JIANGHONG WU et al. Oncology Letters
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
- (2012) Matthew A. Held et al. Cancer Discovery
- EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?
- (2012) Brian P. Pollack OncoImmunology
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
- (2011) A P Algazi et al. BRITISH JOURNAL OF CANCER
- Mechanism of action of the multikinase inhibitor Foretinib
- (2011) Maeva Dufies et al. CELL CYCLE
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Association of activated c-Met with NRAS-mutated human melanomas
- (2011) Chandrani Chattopadhyay et al. INTERNATIONAL JOURNAL OF CANCER
- Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
- (2011) Jin Hyun Cho et al. INVESTIGATIONAL NEW DRUGS
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
- (2011) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
- (2011) Valerie P. Grignol et al. JOURNAL OF IMMUNOTHERAPY
- A phase II study of gefitinib in patients with metastatic melanoma
- (2011) Sapna P. Patel et al. MELANOMA RESEARCH
- Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
- (2011) K. Tworkoski et al. MOLECULAR CANCER RESEARCH
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
- (2010) I. Kenessey et al. CURRENT CANCER DRUG TARGETS
- IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways
- (2010) Wu-Guo Deng et al. MELANOMA RESEARCH
- Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model
- (2010) C. Cullinane et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
- (2009) Natalia Jura et al. CELL
- Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
- (2009) N. Schicher et al. CLINICAL CANCER RESEARCH
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration
- (2009) David Labbé et al. JOURNAL OF NUTRITION
- Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
- (2009) Jade Homsi et al. MELANOMA RESEARCH
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
- Activate and resist: L576P-KIT in GIST
- (2009) E. Conca et al. MOLECULAR CANCER THERAPEUTICS
- Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
- (2009) S. E. Woodman et al. MOLECULAR CANCER THERAPEUTICS
- Ligand-Stimulated VEGFR2 Signaling is Regulated by Co-Ordinated Trafficking and Proteolysis
- (2009) Alexander F. Bruns et al. TRAFFIC
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
- (2009) Doris R. Siwak et al. Journal of Oncology
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- (2008) K B Kim et al. BRITISH JOURNAL OF CANCER
- Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)
- (2008) S. R. Moore et al. CLINICAL CANCER RESEARCH
- Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
- (2008) H. van Cruijsen et al. CLINICAL CANCER RESEARCH
- Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
- (2008) X. Jiang et al. CLINICAL CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24
- (2008) Suhendan Ekmekcioglu et al. CYTOKINE
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib
- (2008) Navratna Vajpai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
- (2008) Alex J Eustace et al. Journal of Translational Medicine
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- IGF1 Promotes Resistance to Apoptosis in Melanoma Cells through an Increased Expression of BCL2, BCL-X(L), and Survivin
- (2007) Caroline Hilmi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now